Back to top
more

Alimera Sciences, Inc. (ALIM)

(Delayed Data from NSDQ)

$8.24 USD

8.24
26,749

-0.17 (-2.02%)

Updated Dec 13, 2019 03:56 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.63%
17.80%
9.42%
5.10%
2.04%
10.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | D Growth | F Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for ALIM

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

Alimera Sciences, Inc. [ALIM]

Reports for Purchase

Showing records 1 - 20 ( 63 total )

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

10/31/2019

Company Report

Pages: 5

3Q19 Financial Results Reported; Reiterate Buy; Reducing PT to $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ALIM

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

10/03/2019

Company Report

Pages: 6

Preliminary Top-Line Revenue for 3Q19 Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

09/04/2019

Company Report

Pages: 6

Imminent Launch of ILUVIEN in Germany for Uveitis; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/01/2019

Company Report

Pages: 6

2Q19 Results Disappoint Due to Sales Force Turnover; Reiterate Buy; Lowering PT to $1.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

06/21/2019

Company Report

Pages: 5

UK NICE Issues Positive Coverage Decision in Posterior Uveitis; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

05/01/2019

Company Report

Pages: 6

1Q19 Financial Results Reported; Reiterate Buy; Raising Price Target to $3

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

03/26/2019

Company Report

Pages: 5

ILUVIEN Approved for Posterior Uveitis in Europe; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

03/07/2019

Company Report

Pages: 5

ILUVIEN Reimbursement Secured in France; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

02/20/2019

Company Report

Pages: 6

2018 Financial Results Reported; Reiterate Buy and Raise Price Target to $2.75

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

01/08/2019

Company Report

Pages: 5

Record Revenues in 4Q18 and Full-Year 2018; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

11/30/2018

Company Report

Pages: 6

New Chief Executive Officer Appointed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

11/27/2018

Company Report

Pages: 5

Iluvien Secures Regulatory Approval in Canada; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

11/07/2018

Company Report

Pages: 6

3Q18 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

09/06/2018

Company Report

Pages: 5

Preferred Stock Exchange Has No Effect on Earnings; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

07/31/2018

Company Report

Pages: 7

Iluvien End User Demand Grew 12% YoY in 2Q18; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

06/12/2018

Company Report

Pages: 6

Iluvien Reimbursement in UK May Expand to Phakic Patients; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/08/2018

Company Report

Pages: 6

1Q18 Financial Results Reported; Reiterate Buy and Lowering Price Target to $2.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

02/23/2018

Company Report

Pages: 5

4Q17 Earnings Preview; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Alimera Sciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

01/22/2018

Company Report

Pages: 6

European Submission for Posterior Uveitis Accepted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party